State Public Policy Initiatives
FORCE is engaged in a variety of state legislative initiatives—affordable access to genetic testing, high-risk “supplemental” cancer screenings, fertility treatments and cancer therapies, banning genetic discrimination, etc.—representing the unique needs of individuals with or at risk of hereditary cancer.
High-risk breast screenings and diagnostic tests
SB134 will require private/commercial health insurers to cover breast screenings (breast MRIs, diagnostic mammograms and breast ultrasounds) with no patient cost-sharing for individuals with a family history of cancer or who have additional factors that may increase their cancer risk.
High-risk breast screenings and diagnostic tests
HB2411 will require private/commercial health insurers to cover breast screenings (breast MRIs, diagnostic mammograms and breast ultrasounds) with no patient cost-sharing for individuals with a family history of cancer or who have additional factors that may increase their cancer risk.
Genetic testing
HB2649 will require private/commercial health insurers to cover genetic counseling and multigene panel testing with no patient cost-sharing for individuals with a family history of cancer.
Genetic counselor licensure
SB1043 will facilitate state licensure of genetic counselors by the American Board of Genetic Counseling (ABGC).
Fertility services
Summary: SB729 will facilitate improved private/commercial insurance coverage of the diagnosis and treatment of infertility, including medically appropriate fertility preservation and in vitro fertilization (IVF).
High-risk prostate cancer screening
HB302-1 will require private/commercial health insurers to cover prostate screenings with no patient cost-sharing for men at increased risk.
High-risk breast screenings and diagnostic tests
HB773/SB932 will require private/commercial health insurers to cover breast screenings (breast MRIs, diagnostic mammograms and breast ultrasounds) with no patient cost-sharing for individuals with a family history of cancer or who have additional factors that may increase their cancer risk.
High-risk colorectal cancer screening
HB2385 will require private/commercial health insurers to cover high-risk colorectal cancer screenings (colonoscopy) with no cost-sharing.
High-risk breast screenings and diagnostic tests
HB4180 will make the language in the state’s breast screening law gender-neutral, changing “woman” to “patient” and will require Medicaid (in addition to private/commercial insurers) to cover breast screenings (breast MRIs, diagnostic mammograms and breast ultrasounds) with no patient cost-sharing for individuals with a family history of cancer or who have additional factors that may increase their cancer risk.
Fertility services
SB773 will facilitate private/commercial insurance coverage (including the State Employees Group Insurance Program) of the diagnosis and treatment of infertility, including medically appropriate fertility preservation, in-vitro fertilization (IVF) and preimplantation genetic diagnosis (PGD).
Genetic testing and associated cancer screenings
HB4562/SB2697 will require private/commercial health insurers to cover genetic testing (not to exceed a $50 copay) for those with a personal or family history of cancer, and coverage of the associated guideline-recommended cancer screenings (deductibles, coinsurance & copays apply).
Breast reconstruction and density notification
HB1058 will require private/commercial health insurers to cover post-mastectomy chest wall reconstruction and aesthetic flat closure. In addition, the bill would require that mammography facilities provide written notice if a patient has dense breast tissue.
High-risk breast screenings and diagnostic tests
HF2489/SF2358 will require private/commercial health insurers to cover breast screenings (breast MRIs, diagnostic mammograms and breast ultrasounds) with no patient cost-sharing for individuals with a family history of cancer or who have additional factors that may increase their cancer risk.
Cancer screenings
HB52 will require private/commercial health insurers and Medicaid to cover all cancer screenings recommended by the National Comprehensive Cancer Network or other guideline organizations with no-cost sharing for the patient.
Breast screenings and diagnostic tests
HB115 will require private/commercial health insurers to cover mammograms, diagnostic and supplemental breast exams with no patient cost-sharing.
Breast screenings and diagnostic tests
H4918 will require private/commercial health insurers to cover medically appropriate breast screenings (breast mammograms, MRIs and ultrasounds) and diagnostic imaging with no patient cost-sharing.
Fertility preservation
Summary: H1041/S598 will facilitate private/commercial insurance coverage of fertility preservation for individuals diagnosed with a medical or genetic condition that may directly or indirectly cause impairment of fertility. Passed as part of the appropriations bill - H4600, Amendment 315/ S4, Amendment 396.
High-risk breast screenings and diagnostic tests
HB1144/SB2263 will require private/commercial health insurers to cover breast screenings (breast MRIs, diagnostic mammograms and breast ultrasounds) with no patient cost-sharing for individuals with a family history of cancer or who have additional factors that may increase their cancer risk.
High-risk breast screenings and diagnostic tests
LB1353 will expand and improve current statutes, requiring private/commercial health insurers to cover breast screenings (breast MRIs, diagnostic mammograms and ultrasounds) for individuals with a family history of cancer or additional factors that may increase their cancer risk with no cost-sharing for the patient.
High-risk breast screenings and diagnostic tests
HB1296 will require private/commercial health insurers to cover breast screenings (breast MRIs, diagnostic mammograms and breast ultrasounds) with no patient cost-sharing for individuals with a family history of cancer or who have additional factors that may increase their cancer risk.
High-risk prostate cancer screening
HB550 will require private/commercial health insurers to cover prostate screenings with no patient cost-sharing for individuals at increased risk.
Fertility preservation
SB1334 will facilitate private/commercial insurance coverage of fertility preservation services for individuals who may face medically-induced infertility.
High-risk breast screenings and diagnostic tests
H7737/S2070 will require private/commercial health insurers to cover breast screenings (breast MRIs, diagnostic mammograms and breast ultrasounds) with no patient cost-sharing for individuals with a family history of cancer or who have additional factors that may increase their cancer risk.
Protections against genetic discrimination
HB4218 will prohibit life, long-term care and disability insurers from using genetic information when considering benefits, fees or coverage determinations.
Fertility services
HB2549/SB2629 will facilitate private/commercial insurance coverage of fertility preservation for individuals diagnosed with cancer.
High-risk breast screenings and diagnostic tests
H621 will require private/commercial health insurers to cover breast screenings (breast MRIs, diagnostic mammograms and breast ultrasounds) with no patient cost-sharing for individuals with a family history of cancer or who have additional factors that may increase their cancer risk.
High-risk breast screenings and diagnostic tests
HB230 will require private/commercial health insurers to cover breast screenings (breast MRIs, diagnostic mammograms and breast ultrasounds) with no patient cost-sharing for individuals with a family history of cancer or who have additional factors that may increase their cancer risk.
Genetic counselor licensure
SB714 will facilitate state licensure of genetic counselors by the American Board of Genetic Counseling (ABGC).
High-risk breast screenings and diagnostic tests
AB117/SB121 will require private/commercial health insurers and Medicaid to cover breast screenings (breast MRIs, diagnostic mammograms and breast ultrasounds) with no patient cost-sharing for individuals with a family history of cancer or who have additional factors that may increase their cancer risk.